Efficacy of rabeprazole in the treatment of symptomatic gastroesophageal reflux disease

Peter J. Kahrilas*, Philip Miner, John Johanson, Lian Mao, Leonard Jokubaitis, Sheldon Sloan

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

33 Scopus citations


The purpose of this study was to assess the rapidity of symptom relief and 4-week efficacy of rabeprazole 20 mg in patients with moderately severe nonerosive gastroesophageal reflux disease. Data were analyzed from 2 similarly designed, double-blind, placebo-controlled, multicenter, U.S. trials. After a 2-week placebo run-in period, patients (N = 261) were randomized to 4 weeks of rabeprazole 20 mg once daily or placebo. Patients kept symptom diaries and scored symptom severity. Median time to first 24-hour heartburn-free interval was 3.5 days for the rabeprazole group compared with 19.5 days for the placebo group (P ≤ .0002). Complete heartburn relief at week 4 was 32% with rabeprazole and 3.8% with placebo (P ≤ .001). Rabeprazole also significantly improved other GERD-associated symptoms (e.g., regurgitation, belching, early satiety) by week 4 compared with placebo (P ≤ .05). Rabeprazole provides fast and potent relief from heartburn and other symptoms of nonerosive gastroesophageal reflux disease.

Original languageEnglish (US)
Pages (from-to)2009-2018
Number of pages10
JournalDigestive diseases and sciences
Issue number11
StatePublished - Nov 2005


  • Gastroesophageal reflux disease symptoms
  • Nonerosive gastroesophageal reflux disease
  • Proton pump inhibitor
  • Rabeprazole

ASJC Scopus subject areas

  • Physiology
  • Gastroenterology


Dive into the research topics of 'Efficacy of rabeprazole in the treatment of symptomatic gastroesophageal reflux disease'. Together they form a unique fingerprint.

Cite this